Skip to content

Study on Individualized Dose Adjustment of Direct Oral Anticoagulants in Elderly Patients with Pulmonary Embolism

Study on Individualized Dose Adjustment of Direct Oral Anticoagulants in Elderly Patients with Pulmonary Embolism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127208
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Interventions

Age >=75 years (elderly group):None
Age <75 years:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult patients with acute symptomatic pulmonary embolism (with or without concurrent deep vein thrombosis) objectively diagnosed by imaging, who have completed the acute phase of anticoagulation and entered the maintenance phase of anticoagulation.

Exclusion criteria

Exclusion criteria: 1. Life expectancy < 3 months; 2. Presence of active major bleeding or obvious bleeding tendency (e.g., recent gastrointestinal bleeding, history of intracranial hemorrhage not assessed as stable, etc.), or judged by the investigator to have unacceptable risk of anticoagulation; 3. Severe liver dysfunction (e.g., Child-Pugh Class C) or significant coagulation abnormalities not attributed to anticoagulation; 4. Severe renal dysfunction (e.g., eGFR < 15 mL/min/1.73m^2 or requiring dialysis) making the use of direct oral anticoagulants (DOACs) inappropriate; 5. Significant thrombocytopenia (e.g., platelet count < 50 × 10^9/L) or other severe hematological disorders affecting bleeding/coagulation assessment; 6. Pregnancy or breastfeeding; 7. Inability to adhere to fixed medication and blood sampling schedules as required by the study (e.g., poor compliance, inability to follow up, etc.).

Design outcomes

Primary

MeasureTime frame
Symptomatic VTE recurrence;Plasma drug concentration (anti-FXa, Cpeak, Ctrough);Coagulation parameters (PT, Factor Xa activity);Genotype (ABCB1, ABCG2, CYP3A4, CYP3A5 SNPs);

Secondary

MeasureTime frame
Fatal or non-fatal pulmonary thromboembolism;

Countries

China

Contacts

Public ContactLi Yiyao

Peking Union Medical College Hospital

liyiyao@pumch.cn+86 10 69155653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026